Overview

Scleroderma Lung Disease

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.

Phase:

Phase 3

Details

Lead Sponsor:

The University of Texas Health Science Center, Houston

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Cyclophosphamide